^
Association details:
Evidence:
Evidence Level:
Resistant: C4 – Case Studies
New
Title:

CMTR1-ALK: an ALK fusion in a patient with no response to ALK inhibitor crizotinib

Excerpt:
NGS result revealed that this tumor specimen harbored a previously unknown CMTR1-ALK fusion variant...treatment was initiated with 250 mg crizotinib per day starting in September 2016. The disease still developed 1 month after drug treatment showing that this patient has no response to crizotinib.
DOI:
10.1080/15384047.2018.1480282